Glycosylated Peptide Market, by Product Type (Monoclonal Antibodies (MABs), Erythropoietin (EPO), Others) and, by Application (Oncology, Blood Disorder, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Glycosylated peptide are used as a mediators of key biological function with unique intrinsic properties with potential to treat variety of diseases. Glycosylation of peptide drugs benefits with key features such as increased half-life, provides extended dosing duration, better solubility, and improved response to the therapy. The key factors that drive the market growth are the benefits of these peptides that show high biological activity, availability of innovative peptides in the market, and rise in incidence of chronic diseases worldwide. However, the intrinsic complexity for manufacturing and high cost of the active pharmaceutical ingredient (API) restricts the market growth. Nevertheless, ongoing R&D activities and increase in investment by the pharmaceutical companies offer ample opportunities to the market growth.

This global market is segmented on the basis of product type such as monoclonal antibodies (MABs), erythropoietin (EPO), and others. Based on application, the market is divided into oncology, blood disorder, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the market include Sandoz International GmbH, Pfizer Inc. Roche Ltd, Teva Pharmaceuticals Industries Ltd, Celltrion Inc., Biocon Ltd., Dr.Reddys Laboratories Ltd, Medtronic plc, Cipla Inc, and Bachem Americas, Inc.

Key Benefits

• The study provides an in-depth analysis of the global glycosylated peptide market along with current trends and future estimations to elucidate the imminent investment pockets.
• It presents a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the market by product assists to understand the various forms of autoimmune disease diagnostic available.
• Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.

  Glycosylated Peptide Market Report Highlights

Aspects	Details
By Product Type	Monoclonal Antibodies (MABs) Erythropoietin (EPO) Others
By Application	Oncology Blood Disorder Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Celltrion Inc., Roche Ltd., Dr.Reddys Laboratories Ltd., Cipla Inc., Teva Pharmaceuticals Industries Ltd., Sandoz International GmbH, Biocon Ltd., Bachem Americas, Inc., Pfizer Inc., Medtronic plc

^*Terms and Conditions Apply